In advance of oral argument in March, hundreds of #pharmaceutical companies & former #FDA ofcls warned #SCOTUS not to second-guess #scientific#experts & said a ruling against FDA would destabilize the #regulatory system & jeopardize investments in #research & #innovation.
Most of the questions from the justices at argument centered on whether the #antiabortion challengers had a #legal right –or #standing – to file. Lawyers defending the drug said the plaintiffs were not directly #harmed.
#SupremeCourt#AbortionPill case
Tue’s oral argument is focused on whether to overrule the #FDA & reimpose restrictions on getting #abortion medication. <2 yrs after #SCOTUS overturned #RoeVWade, the issue of #ReproductiveRights is returning to the high court on Tues as the justices consider whether to limit access to a med used in >60% of US abortions.
The #Biden admin & the manufacturer of #mifepristone are seeking to reverse a lower-court ruling.
The #pharmaceutical industry warned that 2nd-guessing the #FDA will broadly disrupt the nation’s #drug-approval process & stymie private investment in #research.
The case could make it harder to get #MedicationAbortions even in states where #abortion is legal. Allowing #medication abortions to proceed w/o an in-person medical visit has increased #access, particularly for women in #rural areas & others who struggle to go to a clinic in person, allowing them to complete the process from home. #law